Growing evidence suggests that the gut microbiota modulates the efficacy and toxicity of
cancer therapy, most notably immunotherapy and its immune-related adverse effects. The …

Cells are equipped with numerous sensors that recognize nucleic acids, which probably
evolved for defence against viruses. Once triggered, these sensors stimulate the production …

The composition of the gut microbiome can control innate and adaptive immunity and has
emerged as a key regulator of tumor growth, especially in the context of immune checkpoint …

Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented
responses in patients with high-risk hematologic malignancies. However, up to 60% of …

Microorganisms, including bacteria, viruses, fungi, and other eukaryotes, play critical roles in
human health. An altered microbiome can be associated with complex diseases …

Inflammation-associated insulin resistance is a key trigger of gestational diabetes mellitus
(GDM), but the underlying mechanisms and effective interventions remain unclear. Here, we …

Our understanding of how the microbiota affects the balance between response to and
failure of cancer treatment by modulating the tumour microenvironment and systemic …

Gut microbiota was only considered as a commensal organism that aids in digestion, but
recent studies revealed that the microbiome play a critical role in both physiological and …

The gut microbiota has emerged as a key modulator of cancer treatment responses in terms
of both efficacy and toxicity. This effect is clearly mediated by processes impacting the …

Immune checkpoint blockade (ICB) improves outcomes for some patients with advanced or
metastatic cancers. Despite demonstrable progress, many patients do not respond to ICB …